CHICAGO — Individuals with high-risk hepatocellular carcinoma undergoing curative-intent procedures did not experience clinically meaningful deterioration in quality of life or function after adjuvant therapy, phase 3 study results showed.Patient-reported outcomes from the randomized IMbrave050 trial presented at ASCO Annual Meeting suggest that an adjuvant regimen of atezolizumab plus
Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation in HER2 gene
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.